Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of MYK-491 in Patients With Stable Heart Failure With Reduced Ejection Fraction

Trial Profile

Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of MYK-491 in Patients With Stable Heart Failure With Reduced Ejection Fraction

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MYK 491 (Primary)
  • Indications Dilated cardiomyopathy
  • Focus Adverse reactions; Proof of concept
  • Sponsors MyoKardia
  • Most Recent Events

    • 04 Nov 2019 According to a MyoKardia media release, given the favorable safety profile observed to date, the Phase 2a study has been extended to evaluate higher exposures of MYK-491.
    • 28 Oct 2019 According to a MyoKardia media release, full data from this study will be submitted to an upcoming scientific conference for presentation.
    • 28 Oct 2019 Interim results(n=26) published in the MyoKardia Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top